Edition:
United Kingdom

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

180.09USD
6:24pm BST
Change (% chg)

$0.01 (+0.01%)
Prev Close
$180.08
Open
$179.43
Day's High
$181.22
Day's Low
$179.43
Volume
106,186
Avg. Vol
498,757
52-wk High
$186.41
52-wk Low
$136.78

Chart for

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $39,103.64
Shares Outstanding(Mil.): 252.12
Dividend: --
Yield (%): --

Financials

  VRTX.OQ Industry Sector
P/E (TTM): 150.12 85.68 32.76
EPS (TTM): 1.03 -- --
ROI: 12.80 1.79 14.61
ROE: 19.56 3.28 16.33

Vertex cystic fibrosis drug gets expanded approval for use in infants

U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months.

15 Aug 2018

Vertex cystic fibrosis drug gets expanded approval for use in infants

Aug 15 U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months.

15 Aug 2018

BRIEF-Sativa Investments to invest in Canada's Veritas Pharma

* SATIVA INVESTMENTS COMMITS TO C$.02 MILLION INVESTMENT IN CANADIAN-BASED VERITAS PHARMA

21 May 2018

Vertex Pharma profit tops estimates on strong launch of new CF drug

Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.

26 Apr 2018

UPDATE 2-Vertex Pharma profit tops estimates on strong launch of new CF drug

* New CF drug Symdeko Q1 sales $34 mln easily tops expectations

26 Apr 2018

BRIEF-Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor

* VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS

26 Apr 2018

CORRECTED-Vertex Pharma's quarterly profit falls 15.1 percent

April 26 Vertex Pharmaceuticals Inc's quarterly profit fell 15.1 percent, hurt by higher research and development spending.

26 Apr 2018

BRIEF-Vertex Pharmaceuticals Inc Reports Qtrly EPS Of $0.81

* COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BILLION TO $2.80 BILLION

26 Apr 2018

BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln

* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2017 TOTAL COMPENSATION WAS $17.3 MILLION VERSUS $17.4 MILLION IN FY 2016 - SEC FILING Source text (https://bit.ly/2JVKbq6) Further company coverage:

17 Apr 2018

BRIEF-Veritas Pharma Enters Into Share Purchase Agreement With 3 Carbon Extractions Inc.

* VERITAS PHARMA ENTERS INTO SHARE PURCHASE AGREEMENT WITH 3 CARBON EXTRACTIONS INC. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $140.79 -2.09
Pfizer Inc. (PFE.N) $43.97 -0.09
Novartis AG (NOVN.S) CHF81.80 -0.08
Merck & Co., Inc. (MRK.N) $70.83 -0.27
Roche Holding Ltd. (ROG.S) CHF233.00 -2.15
Roche Holding Ltd. (RO.S) CHF234.00 -1.40
Sanofi SA (SASY.PA) €73.86 -0.64
GlaxoSmithKline plc (GSK.L) 1,522.80 -8.60
AbbVie Inc (ABBV.N) $93.40 +1.14
Bristol-Myers Squibb Co (BMY.N) $61.42 -0.83

Earnings vs. Estimates